Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.

Autor: Rupp A; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Centre Munich, Munich, Germany., Bahlmann S; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany., Trimpop N; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany., von Pawel J; Asklepios Lungen-Fachkliniken München-Gauting, Gauting, Germany., Holdenrieder S; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Centre Munich, Munich, Germany.; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Publikováno v: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2024; Vol. 46 (s1), pp. S341-S353.